StockData
JSPRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Jasper Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.48−0.00 (-0.52%)

Close on Oct 19, 2026

Market cap
$13.70M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 9, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 14, 2026After market close–$-0.10–
Q1 FY2026
Ended Mar 31, 2026
May 14, 2026After market close–$-0.04–
Q4 FY2025
Ended Dec 31, 2025
Mar 30, 2026After market close–––
Q3 FY2025
Ended Sep 30, 2025
Nov 10, 2025Before market open–––
Q2 FY2025
Ended Jun 30, 2025
Aug 13, 2025After market close–$-1.74–
Q1 FY2025
Ended Mar 31, 2025
May 12, 2025After market close–$-1.41–
Q4 FY2024
Ended Dec 31, 2024
Feb 27, 2025Before market open–$-1.62–
Q3 FY2024
Ended Sep 30, 2024
Nov 7, 2024Before market open–$-1.24–
Q4 FY2023
Ended Dec 31, 2023
Mar 4, 2024Before market open–$-1.50–
Q2 FY2023
Ended Jun 30, 2023
Aug 11, 2023After market close–$-0.15–
Q1 FY2023
Ended Mar 31, 2023
May 12, 2023After market close–$-0.16–

Press releases

Announcements Jasper Therapeutics filed with the SEC